Page last updated: 2024-11-13

bmn 111

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vosoritide: a biologic analogue of C-type natriuretic peptide, a potent stimulator of endochondral ossification [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	119058036
MeSH ID	M0581404

Synonyms (9)

Synonym
gtpl9068
1480724-61-5
bmn 111
unii-7se5582q2p
7se5582q2p ,
vosoritide [usan:inn]
vosoritide
bmn-111
voxzogo

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" No new adverse effects of vosoritide were detected."	( Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Alanay, Y; Arundel, P; Bacino, CA; Basel, D; Bober, MB; Charrow, J; Day, JRS; Fisheleva, E; Font, RU; Ginebreda, I; Harmatz, P; Hoernschemeyer, D; Hoover-Fong, J; Huntsman-Labed, A; Irving, M; Jayaram, K; Kotani, Y; Leiva-Gea, A; Luna-González, F; Mochizuki, H; Mohnike, K; Ozono, K; Polgreen, LE; Porco, DM; Rutsch, F; Saal, HM; Savarirayan, R; Tofts, L; White, KK; Wilcox, WR; Yasui, N, 2021)	0.62
"Vosoritide treatment has safe and persistent growth-promoting effects in children with achondroplasia treated daily for two years."	( Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Alanay, Y; Arundel, P; Bacino, CA; Basel, D; Bober, MB; Charrow, J; Day, JRS; Fisheleva, E; Font, RU; Ginebreda, I; Harmatz, P; Hoernschemeyer, D; Hoover-Fong, J; Huntsman-Labed, A; Irving, M; Jayaram, K; Kotani, Y; Leiva-Gea, A; Luna-González, F; Mochizuki, H; Mohnike, K; Ozono, K; Polgreen, LE; Porco, DM; Rutsch, F; Saal, HM; Savarirayan, R; Tofts, L; White, KK; Wilcox, WR; Yasui, N, 2021)	0.62

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay ID	Title	Year	Journal	Article
AID1345469	Human Guanylyl cyclase-B (Receptor Guanylyl Cyclase (RGC) family)	2012	American journal of human genetics, Dec-07, Volume: 91, Issue:6	Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	6 (35.29)	24.3611
2020's	11 (64.71)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	29.58 (24.57)
Research Supply Index	3.18 (2.92)
Research Growth Index	4.90 (4.65)
Search Engine Demand Index	32.40 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (29.58)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	5 (27.78%)	5.53%
Reviews	4 (22.22%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (50.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
pamidronate [no description available]	3.18	1	0	phosphonoacetic acid
natriuretic peptide, c-type Natriuretic Peptide, C-Type: A PEPTIDE of 22 amino acids, derived mainly from cells of VASCULAR ENDOTHELIUM. It is also found in the BRAIN, major endocrine glands, and other tissues. It shares structural homology with ATRIAL NATRIURETIC FACTOR. It has vasorelaxant activity thus is important in the regulation of vascular tone and blood flow. Several high molecular weight forms containing the 22 amino acids have been identified.	12.49	21	8
lb-100 LB100: a serine-threonine protein phosphatase 2A (PP2A) inhibitor	2.31	1	0
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	6.91	3	3	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite

Condition	Relationship Strength	Studies	Trials
Achondroplasia, Severe, With Developmental Delay And Acanthosis Nigricans [description not available]	14.41	31	20
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.43	2	0
Achondroplasia An autosomal dominant disorder that is the most frequent form of short-limb dwarfism. Affected individuals exhibit short stature caused by rhizomelic shortening of the limbs, characteristic facies with frontal bossing and mid-face hypoplasia, exaggerated lumbar lordosis, limitation of elbow extension, GENU VARUM, and trident hand. (Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim, MIM#100800, April 20, 2001)	14.41	31	20
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	3.23	1	0
Stunted Growth [description not available]	2.31	1	0
Growth Disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.	2.31	1	0
Infusion Site Adverse Event [description not available]	3.64	1	1
Bone Diseases, Developmental Diseases resulting in abnormal GROWTH or abnormal MORPHOGENESIS of BONES.	2.31	1	0
Acrocephaly Premature closing of the lambdoid and coronal sutures.	3.09	1	0
Craniofacial Dysarthrosis [description not available]	3.09	1	0
Craniosynostoses Premature closure of one or more CRANIAL SUTURES. It often results in plagiocephaly. Craniosynostoses that involve multiple sutures are sometimes associated with congenital syndromes such as ACROCEPHALOSYNDACTYLIA; and CRANIOFACIAL DYSOSTOSIS.	3.09	1	0
Congenital Limb Deformities [description not available]	3	1	0
Nanism [description not available]	3	1	0
Lordosis The anterior concavity in the curvature of the lumbar and cervical spine as viewed from the side. The term usually refers to abnormally increased curvature (hollow back, saddle back, swayback). It does not include lordosis as normal mating posture in certain animals ( = POSTURE + SEX BEHAVIOR, ANIMAL).	3	1	0
Brittle Bone Disease [description not available]	3	1	0
Dwarfism A genetic or pathological condition that is characterized by short stature and undersize. Abnormal skeletal growth usually results in an adult who is significantly below the average height.	3	1	0
Hypophosphatasia A genetic metabolic disorder resulting from serum and bone alkaline phosphatase deficiency leading to hypercalcemia, ethanolamine phosphatemia, and ethanolamine phosphaturia. Clinical manifestations include severe skeletal defects resembling vitamin D-resistant rickets, failure of the calvarium to calcify, dyspnea, cyanosis, vomiting, constipation, renal calcinosis, failure to thrive, disorders of movement, beading of the costochondral junction, and rachitic bone changes. (From Dorland, 27th ed)	3	1	0
Osteogenesis Imperfecta COLLAGEN DISEASES characterized by brittle, osteoporotic, and easily fractured bones. It may also present with blue sclerae, loose joints, and imperfect dentin formation. Most types are autosomal dominant and are associated with mutations in COLLAGEN TYPE I.	3	1	0

chemdatabank.com